LENZ Therapeutics has signed a definitive agreement to merge with Graphite Bio in an all-stock deal to form a late clinical-stage biopharmaceutical company.
The merged company’s lead program focus on treating presbyopia.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,